Habil Khorakiwala

Wockhardt applies to seek USFDA nod for ‘miracle’ antibiotic Zaynich

The Mumbai-based company is eyeing a US launch in FY27, marking a pivotal moment for Indian pharma innovation.

Drug maker Wockhardt rallies over 9 percent as White House exempts pharma imports from nations with trade pacts

While announcing the pharma tariffs, Trump did not specify if the levies would apply over and above the existing tariffs as defined with trade agreements with EU and Japan, and the UK.

Wockhardt rises 10% after antibiotic Zaynich, undergoing clinical trials, facilitates in a liver transplant

Habil Khorakiwala, Chairman of Wockhardt had previously said that once the trials are complete, the company will seek necessary regulatory approvals and hope to be in the market 'some time in 2026'.

Wockhardt, Serum Institute to invest and share profit equally from new UK jab plant: Habil Khorakiwala

Wockhardt chairman Habil Khorakiwala declined comment on reports that Serum is looking to buy a stake in Wockhardt

Wockhardt partners with UK govt for COVID-19 vaccines

The manufacturing will be undertaken at CP Pharmaceuticals, a subsidiary of the company based in North Wales, Wockhardt said in a statement.

Wockhardt antibiotic expected to hit US in FY21, market worth $1.5 bn: Khorakiwala

Wockhardt on Monday said the pay-off of its two-decade old research into antibiotics looks within striking distance, as its drug to treat superbugs is expected to hit the US market somewhere in 2020-21.

No scope of US intervention in Indian pharma cos: Wockhardt

Wockhardt chief Habil Khorakiwala says that Indian generic company as a whole is a competitive industry in US and therefore there is no scope for government intervention there. Anmol Ganjoo of JM Financial says if drug prices come down then Indian pharma companies will benefit.

USFDA issues warning letter to Wockhardt's Ankleshwar plant

USFDA has already banned import of products from the facility into the US market since August 5, 2016.

Won't be ethical for pharmas to bring back banned drugs: Expert

The government had banned the FDC medicines including popular names like Corex cough syrup, Vicks and D-cold on March 10 terming them a 'risk' to humans.

CP Pharma under FDA lens, will reply in 3 weeks: Wockhardt Chief

In a blow to Wockhardt, the US FDA has issued a warning letter to company's US subsidiary CP Pharma.

IACC Convention: Pharma & the USFDA jigsaw

Watch the interview of DG Shah, Habil Khorakiwala, KG Ananthakrishnan, Nandkumar Chodankar, SK Nanda, Sudhansh Pant to CNBC-TV18‘s Ekta Batra where they spoke about issues that standout in terms of India and America and the pharmaceutical sector.

Need to speed up process of granting patents: Khorakiwala

The recently launched National Intellectual Property Rights (IPR) policy is a step in the right direction and towards creating an ecosystem for innovation, and it also brings clarity on India's position on IPR framework, he said, adding that a "not so friendly" clinical research environment prevails in the country.

R&D tax deduction unlikely to impact Wockhardt: CEO

In an interview with CNBC-TV18, Khorakiwala said Wockhardt will maintain a double digit growth target for FY17 and expects Indian operations to grow 15-20 percent while UK operations should grow within 15 percent.

All 9 USFDA observations will be resolved in 3 months: Wockhardt

Habil Khorakiwala, Founder, Chairman and Group CEO, Wockhardt says all facilities were inspected in the past six months and none of the US FDA observations are critical in nature, while adding that all these observations will be resolved in next 2-3 months

Will not do any out-licensing in near-term: Wockhardt

Habil Khorakiwala, Founder, Chairman and Group CEO, Wockhardt says US FDA granting a QIDP status to WCK 5222 drug makes it the only company globally to receive this status for its fourth drug.

Wockhardt gets USFDA nod to market pain-relieving drug

The company has received final approval from the US Food and Drug Administration (USFDA) to market 5mg/5ml of Oxycodone HCl liquid, Wockhardt Ltd said in a filing to the BSE.

Wockhardt hopeful of early resolution of USFDA row

Pharma major Wockhardt on Friday said it is hopeful of early resolution of the issues with the US Food and Drug Administration (FDA), which has hit company's performance severely over the past few quarters.

Wockhardt hopes to resolve FDA ban on two plants in FY16

A resolution of the lapses would allow Wockhardt to resume exports from its two main India plants to the United States, a market that previously accounted for half of the drugmaker's global sales.

Hopeful of US FDA issue getting resolved soon: Wockhardt

Habil Khorakiwala said the US FDA has completed its inspection at the Waluj facility. The US FDA also visited the Chikalthana and Aurangabad plans, he said.

Expect US FDA to visit remaining facilities soon: Wockhardt

Habil Khorakiwala, chairman, Wockhardt Ltd addressed the media after the US health regulator said it did not find any issues with respect to data security and control measures at Chikalthana plant in a recent inspection.

Meet the Khorakiwalas: Gen-Next promoters of Wockhardt

Wockhardt has had a fair share of difficult times too. In 2008, the pharma company‘s net worth had eroded to near bankruptcy. Global financial crisis and major foreign exchange losses had hurt it as well. To tide over the crisis, the company decided to go in for CDR in 2009.